Literature DB >> 6095457

Targeting of daunorubicin by association with DNA or proteins: a review.

A Trouet, G Jollès.   

Abstract

Mesh:

Substances:

Year:  1984        PMID: 6095457

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


× No keyword cloud information.
  6 in total

1.  Evaluation of pullulan-functionalized doxorubicin nanoparticles for asialoglycoprotein receptor-mediated uptake in Hep G2 cell line.

Authors:  Swati A Guhagarkar; Sharmila B Majee; Abdul Samad; Padma V Devarajan
Journal:  Cancer Nanotechnol       Date:  2011-01-27

2.  Reduced cardiotoxicity of doxorubicin given in the form of N-(2-hydroxypropyl)methacrylamide conjugates: and experimental study in the rat.

Authors:  T K Yeung; J W Hopewell; R H Simmonds; L W Seymour; R Duncan; O Bellini; M Grandi; F Spreafico; J Strohalm; K Ulbrich
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

3.  Low molecular weight proteins as carriers for renal drug targeting: naproxen coupled to lysozyme via the spacer L-lactic acid.

Authors:  E J Franssen; F Moolenaar; D de Zeeuw; D K Meijer
Journal:  Pharm Res       Date:  1993-07       Impact factor: 4.200

4.  Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. II. Evaluation of daunomycin conjugates in vivo against L1210 leukaemia.

Authors:  R Duncan; P Kopecková; J Strohalm; I C Hume; J B Lloyd; J Kopecek
Journal:  Br J Cancer       Date:  1988-02       Impact factor: 7.640

5.  Site-specific DNA-doxorubicin conjugates display enhanced cytotoxicity to breast cancer cells.

Authors:  Christopher H Stuart; David A Horita; Michael J Thomas; Freddie R Salsbury; Mark O Lively; William H Gmeiner
Journal:  Bioconjug Chem       Date:  2014-02-06       Impact factor: 4.774

6.  Dimeric DNA Aptamer Complexes for High-capacity-targeted Drug Delivery Using pH-sensitive Covalent Linkages.

Authors:  Olcay Boyacioglu; Christopher H Stuart; George Kulik; William H Gmeiner
Journal:  Mol Ther Nucleic Acids       Date:  2013-07-16       Impact factor: 10.183

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.